IgG_{4} Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes by Chappel, J.A. et al.
  
 




IgG_{4} Pf NPNA-1 a human anti-Plasmodium falciparum 
sporozoite monoclonal antibody cloned from a protected 
individual inhibits parasite invasion of hepatocytes. 
 
Jonatha A. Chappel1 
Michael R. Hollingdale2,3 
Angray S. Kang1 * 
 
1
 Department of Molecular Biology, The Scripps Research Institute, USA 
2
 Department of Biology, University of Leeds, UK, MRH 
3 Current address: MRH, Global Affairs, USA 




This is an electronic version of an article published in Human Antibodies, 13 (3). 
Chappel, Jonathan A. and Hollingdale, Michael R. and Kang, Angray S., IgG_{4} Pf 
NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody 
cloned from a protected individual inhibits parasite invasion of hepatocytes, pp. 91-96.  
Copyright © (2004), with permission from IOS Press. 
 






The Eprints service at the University of Westminster aims to make the research output of the 
University available to a wider audience.  Copyright and Moral Rights remain with the authors 
and/or copyright owners. 
Users are permitted to download and/or print one copy for non-commercial private study or 
research.  Further distribution and any use of material from within this archive for profit-
making enterprises or for commercial gain is strictly forbidden.    
 
 
Whilst further distribution of specific materials from within this archive is forbidden, you may 
freely distribute the URL of the University of Westminster Eprints (http://eprints.wmin.ac.uk). 
 
In case of abuse or copyright appearing without permission e-mail wattsn@wmin.ac.uk. 
Human Antibodies 13 (2004) 91–96 91
IOS Press
IgG4 Pf NPNA-1 a human anti-Plasmodium
falciparum sporozoite monoclonal antibody
cloned from a protected individual inhibits
parasite invasion of hepatocytes
Jonathan A. Chappela, Michael R. Hollingdaleb,c and Angray S. Kanga,d,∗
aDepartment of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA
92037, USA
bDepartment of Biology, University of Leeds, UK, MRH
cCurrent address: MRH, Global Affairs, NIAID, 9000 Rockville Pike, Bethesda, MD 20852, USA
E-mail: mhollingda@niaid.nih.gov
dCurrent address: ASK, Antibody Technology, Avanir Pharmaceuticals, 11388 Sorrento Valley Road, San Diego,
CA 92121, USA
Tel.: +1 858 622 5294; Fax: +1 858 658 7458; E-mail: akang@avanir.com
Abstract. Malaria is one of the world’s most devastating diseases, and Plasmodium falciparum (Pf) causes significant mortalities
particularly in Sub-Saharan Africa. The rise and spread of multi-drug resistant strains of the parasite has coincided with an era of
increased travel to malaria endemic regions. In the absence of an effective vaccine against malaria it may be possible to utilize
human monoclonal antibodies against the stage transmitted by mosquito bites (sporozoites) as a prophylactic to prevent infection.
We report the characterization of an engineered human IgG4 monoclonal antibody against Pf sporozoite cloned from a protected
individual recognized the sporozoite surface and inhibited sporozoite invasion of human hepatocytes in vitro.
The fully human monoclonal antibody PfNPNA-1 IgG4 against (NPNA)3 specifically labels Plasmodium falciparum in an IFA.
This antibody also inhibits Plasmodium falciparum sporozoite invasion of human hepatocytes HepG2-A16 in a dose dependent
manner in an in vitro assay. PfNPNA-1 IgG4 is a promising candidate for evaluation for the prevention of malaria.
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1. Introduction
Malaria is an infectious disease which threatens pub-
lic health in regions of the world where more than a
third of the human population reside (approximately
2.2 billion) [1,2]. A number of vaccine candidates have
been evaluated for the prevention of either infection
or disease, and while the results have been encourag-
ing, an effective vaccine is still years away [3]. The
∗Corresponding author.
risk to travellers of malaria infection has increased with
the emergence and spread of drug resistant strains of
the parasite [4], and the need for new effective pro-
phylactic agents is urgent. Studies carried out more
than half a century ago showed that immunization with
radiation-attenuated Plasmodium sporozoites, the in-
fectious stage of the malaria parasite, could confer pro-
tective immunity [5,6]. The role of specific antibody
in such protection was demonstrated with passive ad-
ministration of murine monoclonal antibodies directed
against the major repeat epitope of the circumsporo-
zoite protein (CSP), which prevented malaria in na ı¨ve
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animals [7]. The corresponding epitope of the hu-
man malaria parasite Plasmodium falciparum CSP [8]
is contained within repeats of the tetramer peptide
(NPNA)n [9,10]. However attempts to generate and
maintain protective immunity with repeat peptide based
vaccines have been inadequate, whilst immunization
with attenuated Pf sporozoites induced anti-repeat an-
tibody and protective immunity in many human volun-
teers [11–14]. Analysis of antibody responses in 5 vol-
unteers immunized with irradiated Pf sporozoites im-
plied that induction of anti-repeat antibodies correlated
with protection [15]. Moreover the long term persis-
tence of sterile immunity in a volunteer immunized with
irradiated Pf sporozoites also correlated with the main-
tenance of high levels of antibodies against the repeat
epitope [16]. Due to the T-cell independent activation
of B-cells thought to occur with repetitive antigens [17]
it is unlikely that that high levels of high affinity specific
anti-repeat antibodies will be maintained via conven-
tional immunization with subunit based recombinant
vaccines encoding the repeat epitopes. The vaccines
however may confer short-term protection, but this can-
not be guaranteed for all recipients, since the responses
to the vaccines are dependent on each individual. One
possible way around this problem is to administer a
known anti-parasite inhibitory antibody at a level com-
mensurate with predicted protection. Previously we re-
ported the isolation of PfNPNA-1 a fully human anti-Pf
sporozoite antibody derived from an immune protected
individual [18]. Briefly, peripheral blood lymphocytes
donated by a protected Pf sporozoite immunized indi-
vidual were used to recapitulate the antibody repertoire
in a phage display library. The library was accessed
for antibody fragments binding to the repeat epitope
(NPNA)3. The specific anti-repeat antibody response
appeared to be restricted to a single VH /VL combina-
tion designated PfNPNA-1. In contrast, many distinct
mAbs have been isolated from mice immunized with
either sporozoites [19,20] or (NANP)n-based peptide
immunogens [21], some of which inhibit invasion of
hepatocytes. Here we describe a fully human Pf NPNA-
1 IgG4/κ monoclonal antibody candidate for develop-
ment for the prevention of P. falciparum malaria.
2. Materials and methods
2.1. PfNPNA-1 human IgG4 assembly
For expression of whole human IgG4 in eukary-
otic cells two plasmids pSG5LCDR3 and pSGHCDR-
G4, which respectively encoded the light and heavy
chains of the humanized monoclonal antibody OKT4
(IgG4/k) ligated into pSG5 (Stratagene, La Jolla, CA),
were modified by inserting the VH and VL genes of
PfNPNA-1 [18]. The constructs were evaluated in a
transient transfection assay. The two plasmids were
mixed in equimolar amounts and transfected into 293
cells (transformed human primary embryonal kidney
cells, ATCC # CRL-1573) with lipofectamine (Invit-
rogen, Carlsbad, CA), according to the manufacturers
guidelines. PfNPNA-1 IgG4 was recovered from cul-
ture medium using Protein-A sepharose (Pharmacia,
Piscataway, NJ) and quantified by ELISA. To estab-
lish a stable transfectant, the genes encoding the two
chains were transferred into a modified single vector
pcDNA3.1/zeo (Invitrogen, Carlsbad, CA). The cell
culture, transfection, and cloning were carried out as
described by Dreier [22]. The supernatants of isolated
colonies were assayed for repeat epitope binding by
ELISA and selected IgG4 producers were expanded.
2.2. Indirect immunofluorescence assay
Printed multiwell slides coated with P. falciparum
NF54 strain sporozoites were used unfixed. Antibodies
were applied to the slides and incubated at 37◦C in a hu-
mid container as follows. Slides were blocked with 4%
BSA in PBS for 1 h. Antibodies diluted in PBST were
applied for 2 h, the slides were washed 4× with PBS
and fluoroscein-conjugated anti-human k light chain or
anti-mouse IgG (Sigma, St Louis, MO) were applied,
diluted 1:25 in PBST. After 2 h slides were washed
as before and mounted in SlowFade anti-fade reagent
(Molecular Probes, Eugene, OR) and viewed by fluo-
rescence microscopy. Initially a dilution limit point was
determined for each antibody preparation and images
of staining captured.
2.3. Inhibition of P. falciparum invasion of
HepG2-A16 cells
The assays were performed essentially as described
by Hollingdale [23]. Human hepatoma (HepG2-A16)
cells were cultured at 37◦C in 5% CO2 mixed with air
in MEM supplemented with 10% heat inactivated fetal
bovine serum, 50 U/ml Penicillin and 50 µg/ml strep-
tomycin. The purified monoclonal antibodies were di-
luted from 20, 10, 5, 2.5 µg/ml in culture medium. Con-
trol cultures received mouse mAb 36 to Pf CSP [24],
or no antibody. Viable P. falciparum NF54 sporozoites
were isolated from the salivary glands of laboratory
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Table 1
Recombinant antibodies bind to P. falciparum sporozoites in an IFA:
Determination of dilution limit point (DLP). Antibodies were di-
luted and applied to slides coated with Pf sporozoites, and incubated
at 37◦C in a humid container as follows Printed multiwell slides
coated with PF NF54 strain sporozoites were used unfixed. Slides
were blocked with 4% BSA in PBS for 1 h. Antibodies diluted in
PBST were applied for 2 h, the slides were washed 4x with PBS and
fluoroscein-conjugated anti-human k light chain or anti-mouse IgG
(Sigma) were applied, diluted 1:25 in PBST. After 2 h slides were
washed as before and mounted in SlowFade anti-fade reagent (Molec-
ular Probes) and viewed by fluorescence microscopy and scored vi-
sually for parasite staining. The dilution limit point (DLP) is defined
as the concentration of antibody binding sites below which a clear
surface immunofluorescence of sporozoites is no longer visible
Antibody Dilution Limit Point (M)*
2A10 ∼1× 10−10
PfNPNA-1 VH/k ∼8 × 10−9
PfNPNPA-1 IgG4 ∼5× 10−10
PfNPNA-1 IgG1 ∼3 × 10−9
Vol-IgG ∼3 × 10−7
bred Anopheles stephensi mosquitoes infected by mem-
brane feeding on blood obtained from in vitro culture of
the parasite. Salivary glands were pooled in heat inac-
tivated human serum and disrupted in a tissue grinder.
Sporozoites were counted, diluted and ∼20,000 para-
sites added to each culture well and incubated for a fur-
ther 3 h, rinsed twice with Dulbecco’s PBS, fixed with
methanol and rinsed twice with PBS. Sporozoites that
had entered cells were visualized in fixed cultures by
immunoperoxidase antibody assay (IPA) [23]. The IPA
was carried out by first treating the fixed cultures with
mAb 36 followed by incubation with rabbit anti mouse
immunoglobulin conjugated with HRP and stained with
DAB. The numbers of parasites present in the entire
preparation were counted on a Leitz microscope at 40×
magnification with a blue filter.
3. Results
3.1. Indirect immunofluorescence assay
The recombinant human antibodies label sporozoites
in an IFA and compare favorably with the in vitro pro-
tective mAb 2A10 [19,25] as shown in Fig. 1. A di-
lution limit point determination compared the various
antibody preparations in the IFA and again the results
were very similar to the murine 2A10 as shown in Ta-
ble 1. Since the sporozoites were unfixed and therefore
impermeable, we infer that the antibodies were only
recognizing the sporozoite surface.
Fig. 1. Recombinant antibodies bind to P. falciparum sporozoites in
an indirect immunofluorescence assay (IFA) Antibodies were diluted
and applied to slides coated with unfixed Plasmodium falciparum
sporozoite. The following antibody dilutions used; panel A, mAb
2A10 (∼17 µg/ml), panel B, PfNPNA-1 IgG4 (0.5 µg/ml), panel C,
PfNPNA-1 IgG1 (0.5 µg/ml), panel D, PfNPNA VH /κ (17 µg/ml).
The scale bar in panel D represents 25 µm. The PfNPNA-1 IgG1
was assembled and expressed in baculoviral expression system by J.
Donald Capra and Kathy Potter at University of Texas South West-
ern [30].
3.2. Inhibition of P. falciparum invasion of
HepG2-A16 cells
The potential of this antibody was evaluated by its
efficacy in inhibition of sporozoite invading hepato-
cytes in an in vitro assay [23]. As little as 10 µg/ml
whole IgG4 reduced sporozoite invasion of hepatocytes
by 74%. This inhibition was dose dependant with 5
and 2.5 µg/ml resulting in 58% and 44% inhibition of
sporozoite invasion respectively as shown in Table 2.
This degree of inhibition, correlates well with efficacy
of murine mAb directed against the repeat in similar
assays [23]. At the maximum level tested (20 µg/ml
antibody) the protection did not increase. The murine
positive control IgM mAb 36 however, conferred 91%
inhibition at 10 µg/ml.
4. Discussion
It is well established that polymeric proteins can
stimulate B-cells without the help of T-cells [17]. This
activation of B-cells is mediated via cross-linking of
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Table 2
Human monoclonal antibody PfNPNA-1 IgG4 inhibits P. falciparum sporozoite invasion of HepG2-A16 cells.
Human hepatoma (HepG2-A16) were cultured at 37◦C in 5% CO2 mixed with air in MEM supplemented
with 10% heat inactivated fetal bovine serum, 50 U/ml Penicillin and 50 µg/ml streptomycin. The purified
monoclonal antibodies were diluted from 20, 10, 5, 2.5 mg/ml in culture medium. Viable P. falciparum NF54
sporozoites were counted and ∼20,000 parasites added to each culture well and incubated for a further 3 h,
rinsed twice with Dulbecco’s PBS, fixed with methanol and rinsed twice with PBS. Sporozoites that had
entered cells were visualized in fixed cultures by immunoperoxidase antibody assay (IPA). The numbers of
parasites present in the entire well were counted on a Leitz microscope at 40×magnification with a blue filter.
The total numbers of parasites from two independent wells were added together prior to determining the %
inhibition. % inhibition = 180 – (invasion events) × 100/180
Antibody Concentration µg/ml Number of Invaded Sporozoites per well n = 2 % Inhibition
mAb 36 10 11, 5 91
PfNPNA-1 IgG4 20 37, 19 68
PfNPNA-1 IgG4 10 22, 25 74
PfNPNA-1 IgG4 5 41, 35 58
PfNPNA-1 IgG4 2.5 54, 46 44
No Antibody 0 105, 75 0
the B-cell surface Ig through specific interactions of
the binding sites. The consequence of this route of
B-cell stimulation is the lack of formation of germi-
nal centers, lack of somatic mutations and the failure
to establish real memory. These antibodies tend to be
predominantly IgM with some class switching to IgG
with low affinity, yet retain a physiologically relevant
avidity. This may be occurring in the natural human
immune response against the P. falciparum CS protein
repeat (NPNA)n. Antibody phage display technology
is based on affinity selection [26]. Invariably, it selects
for the antibody fragment with the highest affinity for
the selecting ligand. Despite exhaustive searching of
a human antibody fragment phage display library de-
rived from a Pf sporozoite immunized (protected) donor
PBLs only a single antibody was recovered designated
Pf NPNA-1 VH /κ [18]. The binding affinity of the
monovalent Pf NPNA-1 VH /κ for the repeat peptide
was in the µM range.
The various recombinant human antibodies based on
the PfNPNA-1 VH /VL sequences all label sporozoites
in an IFA and compared favorably with the in vitro
protective mAb 2A10. Moreover the dilution limit
point determinations compared the various antibody
preparations in the IFA and were very similar to the
murine 2A10 as shown in Table 1. The IgG1 and IgG4
had comparable binding characteristics in the IFA and
similar dilution limit points.
The antibody titers against sporozoite in the sera of
individuals living in endemic regions tends to increase
with age [27], and this also correlates with naturally
acquired immunity [28]. Natural infection follows sea-
sonal patterns in which the antibody response may rise
after exposure, but is usually too late to be preventa-
tive and then wanes until the next season, and then
the pattern repeats. We speculate that natural protec-
tion against the sporozoite may be correlated to levels
of specific antibody in the circulation at the time of
exposure and the subsequent development of cell me-
diated immunity. However we further speculate that
the continuous presentation of CS proteins may be re-
quired to maintain a high level of anti-CS antibody re-
sponse. Hepatocytes infected with developmentally ar-
rested parasites, as a result of irradiation, may continue
to produce and release CS protein in such cases. This
is an obstacle for conventional vaccination. Indeed an
immunization protocol establishing a chronic release of
CS proteins may be an ideal vaccine [13]. However un-
til such a concept is developed further, the administra-
tion of human monoclonal IgG antibody may provide
an alternative passive immunization route to protection.
The passive immunization approach is independent of
factors that impose limits on conventional active vacci-
nation strategies, such as the nature of the antigen and
adjuvant effects. Also, the natural restrictions imposed
by the requirements to be effective in a broad range
of human leukocyte class I and II antigens (HLA) for
effective antigen presentation leading to induction and
maintenance of immunity is negated [29]. This can-
didate prophylactic antibody is directed against the re-
peat epitope (NPNA)3 fortunately which is conserved
within the CS protein of P. falciparum isolates from dif-
ferent regions [10,19], and thus should be broadly ef-
fective against all P. falciparum. Moreover the tandem
arrays of repeats on the CS protein molecule reduce the
likelihood of variants arising, which completely disrupt
the epitope and thus evade antibody recognition. Fi-
nally, with the administration of a human monoclonal
antibody of desired affinity, specificity and at a level
required, effective protection can be assured for the
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period of risk to parasite exposure. Polyclonal anti-
bodies induced against the repeat epitope by various
procedures have been correlated to protection [15,16].
It has been estimated that as little as 15–19 µg/ml of
specific IgG may be sufficient to provide complete pro-
tection against malaria infection. The use of pooled
immunoglobulin preparation to confer passive protec-
tion is no longer a therapeutic option due to the risk
of transmission of HIV, HBV, HCV and other blood
borne infectious diseases. Hence, in the absence of
an effective vaccine for the prevention of malaria and
the appearance of multi-drug resistant parasites, reduc-
ing the effectiveness of conventional chemoprevention,
human monoclonal antibodies may prove to be an ef-
fective safe prophylactic agent for the prevention of P.
falciparum malaria.
The fully human monoclonal antibody PfNPNA-1
IgG4 against (NPNA)3 specifically labels Plasmodium
falciparum in an IFA. This antibody also inhibits Plas-
modium falciparum sporozoite invasion of human hep-
atocytes in a dose dependent manner in an in vitro as-
say. The in vitro data suggest that this antibody may
play a role in the prevention of malaria infection.
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